New appointment at Tris Pharma
This article was originally published in Scrip
Tris Pharma (US), a speciality pharmaceutical company focused on the development of drug delivery technologies, has appointed Peter Ciano vice-president of corporate development. He has been working for Tris as a business development consultant for more than eighteen months, and will now lead and manage the company's commercial activities for its brand side of the business.
You may also be interested in...
The Italian firm's move to license Isturisa from Novartis last year is paying dividends already and Recordati has already tripled its peak sales forecast for the Cushing's therapy.
Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-two guidance documents have been posted on the tracker since its last update.